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Abstract
The quantification of the HIV integrase inhibitor raltegravir in blood plasma is described using 
solid phase extraction (SPE) coupled with an accurate high-performance liquid chromatography 
assay with ultraviolet (UV) detection. The method was validated over the range of 20–
10,000ng/mL using simple sample preparation and chromatography. The SPE method was 
optimized to be selective and highly efficient. The buffer’s ionic strength and pH were optimized 
for retaining RAL and the internal standard on the column, the percentage of methanol was 
optimized in the cleaning step to remove unwanted plasma contaminants, and the type and amount 
of acid was optimized for complete elution of the compounds. This method has no interference 
with other potentially co-administered antiretrovirals or common drugs. Average recoveries for 
the extraction method were consistently high: 90% for raltegravir and 90% for the internal 
standard diazepam. This method was found to be accurate and precise. Within day (n=6) and 
between day (n=18) accuracies ranged from 97.5% to 104.4%. Within-day (n=6) and between-day 
(n=18) precision ranged from 1.4% to 3.8%, and from 2.4% to 7.9%, respectively. This is the first 
published method to use simple UV technology and reliable SPE extraction methodology for the 
quantification of raltegravir in human plasma. This method can be easily implemented in most 
bioanalytical laboratories.
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1. Introduction
Raltegravir (MK-0518 or ISENTRESS®) is a human immunodeficiency virus integrase 
strand transfer inhibitor, preventing the insertion of viral DNA into the genome of the cell 
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and consequently, preventing viral replication [1]. The chemical name for raltegravir (RAL) 
is N-[(4-Fluorophenyl) methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-
methyl-1,3,4-oxadiazol-2-yl)carbonyl]-6-oxo-4-pyrimidinecarboxamide monopotassuim salt 
(Fig 1). During clinical trials, raltegravir was proven effective at reducing HIV RNA in 
treatment-naïve patients in addition to those with multidrug-resistant strains of the virus [2, 
3]. To monitor drug concentrations in patients, in addition to studying drug-drug 
interactions, a bioanalytical assay for the accurate measurement of RAL in biological fluids 
is needed.
Currently, three bioanalytical methods for quantification of RAL have been published [4–6]. 
Two of these methods use HPLC with MS/MS detection [4,5] and one uses fluorescence 
detection [6]. The most recent publications [5,6] use the same liquid-liquid extraction 
method as that of Merschman et al. [4]. Since these technology platforms are not available in 
every bioanalytical laboratory, there is still a need for a standard method that can be applied 
to bioanalytical laboratories globally. Therefore, our objective was to develop an accurate, 
specific and precise bioanalytical method using small plasma volumes with high-efficiency 
solid phase extraction and a standard binary HPLC coupled with a simple UV detection 
method.
Therapeutic strategies for the treatment of HIV require administration of at least three 
antiretroviral drugs from a variety of different drug classes. RAL may be used in 
combination with nucleoside(tide) reverse transcriptase inhibitors in addition to either 
nonnucleoside reverse transcriptase inhibitors or a ritonavir-enhanced protease inhibitor. 
Therefore, an analytical method for analyzing RAL in biological fluids on routine basis must 
ensure that no interference occurs from the biological matrix or from other antiretrovirals to 
affect the accuracy and precision of the final concentration. Therefore, a solid phase 
extraction (SPE) technique was developed by focusing on selectivity, recovery and 
concentrating RAL four-fold for senstivity. The final HPLC method developed is a simple 
and reliable one for routine analysis of raltegravir in the presence of any other ARV’s after a 
highly efficient solid phase extraction method.
2. Experimental
2.1. Chemicals and solvents
Raltegravir monopotassuim salt was obtained from Merck Research Laboratories (Rahway, 
NJ, USA). Diazepam, used as the internal standard for this assay, was purchased from 
Sigma Chemical Company (St. Louis, MO, USA). All other analytical grade antiretroviral 
agents were obtained from the NIH AIDS Research & Reference Reagent Program 
(McKesson HBOC BioServices, Rockville, MD, USA). HPLC-grade solvents (water and 
methanol), ammonium acetate, trifluroacetic acid (TFA), perchloric acid (PCA), acetic acid 
and tetrabutylammonioum phosphate (TBAP) were purchased from Fisher Scientific 
(Norcross, GA, USA). Human free drug plasma was purchased from Biological Specialty 
Corporation (Colmar, Pa, USA). Purified compressed nitrogen gas was obtained from 
National Welders Supply (Charlotte, NC, USA).
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A high-performance liquid chromatography (HPLC) system consisting of an Agilent 
Technologies (Wilmington, DE, USA) Model HP1100 binary pump, an HP1100 degasser, 
an HP1100 auto sampler, an Agilent 1100 UV-DAD-detector, and HP ChemStation software 
(Version A.10.03) on an IBM computer (operated by Windows XP professional), was used 
for this method. Waters Symmetry®C18, 3.5μm, 3.0x150mm, Waters Atlantis®C18, 3.0μm, 
3.0x150mm (Waters, Milford, MA, USA) Agilent Zorbax® SB C18, 3.5 μm (Agilent, 
Welmington, DE, USA), and Restek® IBD, C18, 3.0 μm, 3.2x100mm (Restek, Bellefonte, 
PA, USA) were tested during the development of this method. A Turbovap LV evaporator 
from Zymark (Hopkinton, MA, USA) was used in sample processing.
2.3. Preparation of standards
A clear stock solution of raltegravir was prepared at a concentration of 1 mg/mL. 
Accurately, 5.46 mg of raltegravir potassium dry base powder (molecular weight 482.51 g) 
was weighed and dissolved in 5 mL HPLC-grade water in a 5 mL volumetric flask. The 
master stock solution was prepared by diluting 1.0 mL of the stock solution with 9.0 mL of 
HPLC-grade water to a final concentration of 100 mgL−1. This 100 mgL−1 master stock 
solution was used to prepare seven working solutions (0.02, 0.05, 0.2, 0.5, 1.0, 2.0, 5.0 and 
10.0 mgL−1) in drug-free pooled plasma. Quality control (QC) samples at 0.06, 0.6 and 6.0 
mgL−1 were prepared from another 100 mgL−1 preparation, with serial dilutions in pooled 
human plasma. This plasma was devoid of any drugs, and obtained from the whole blood of 
male and female subjects, anticoagulated with Na EDTA (Biological Specialty Corporation, 
PA, USA).
2.4 .Internal standard (I S) preparation
Diazepam (10 mg) was dissolved in a 50:50 solution of methanol and water to achieve a 
final concentration of 1.0 gL−1 (stock solution). From this solution, an aliquot was diluted in 
HPLC-water to a final concentration of 0.5 mgL−1 (working solution).
2.5. Sample pre-treatment
Blood samples were collected in sodium EDTA tubes and centrifuged at 2800 rpm for 15 
min at 4 oC. Plasma was transferred to clean cryovials and stored at −70 °C. Prior to 
extraction, all patient plasma samples were heated for 60 minutes at 58°C to inactivate the 
HIV virus. All patient samples, blanks, calibrators and quality control samples were brought 
to room temperature before extraction.
2.6. SPE method
Solid phase extraction Bond Elute® columns (1.0mL, 100mg, Varian, Harbor City, CA, 
USA) were placed in a vacuum elution manifold (20-SPE system, Waters, Milford, MA, 
USA). The cartridges were rinsed with 1.0 mL of methanol, conditioned with 1.0 mL of 150 
mM ammonium acetate (pH 5.0). With the vacuum off, 100μL of the internal standard 
(diazepam, 0.5 mg mL−1) was added, followed by the 100 μL plasma sample (blank, 
calibrators, QC’s and patient samples). The 200 μL were allowed to pass through the column 
bed with minimal suction. The column was further washed with 1.0 mL of 5% methanol in 
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50 mM ammonium acetate buffer (pH 7.0), and the bed was suctioned dry for at least 1 
minute. The analyte and internal standard were then eluted with 400 μL of 1.5% glacial 
acetic acid (99.9%) in methanol in a clean 1.5 mL eppendorf tube. The eluent was 
evaporated to dryness under a nitrogen stream at 35°C, and the residue was reconstituted 
with 50 μL mobile phase (A). The resulting solution was carefully vortex-mixed for 30 
seconds and centrifuged at 12 000 rpm for 3 minutes. The supernatant was transferred to 200 
μL HPLC microvials (Agilent Technologies) and 40 μL injected onto the column.
The recovery of both raltegravir and diazepam (IS) after solid phase extraction were 
determined by comparing the observed peak area in an extracted plasma sample, to those of 
the non-processed standard solution. A composite of raltegravir and diazepam were made at 
three concentrations (0.06, 0.60, and 6.0 mgL−1) in plasma and at three concentrations (0.12, 
1.20, and 12.0 mgL−1) in mobile phase.
2.7. High Performance Liquid Chromatographic conditions
Chromatographic separation was achieved using a Symmetry® C18 analytical column 
(150mm x 3.0mm, 3.5 μm particle size, Waters Corp., Milford MA, USA), with a 
Symmetry® C-18 guard column (20mm x 3.9mm, 5 μm particle size, Waters Corp.). The 
absorbance was monitored at 218nm (λmax). The two mobile phase components were as 
follows: Mobile Phase (A): 25mM sodium dihydrogenphosphate buffer and 0.5mM TBAP 
(pH 4.0). This solution was filtered through a 0.45μm membrane filter (Millipore, Milford, 
MA, USA) before mixing with acetonitrile (20%), and Mobile Phase (B): 19.5% 
acetonitrile, 80% methanol and 0.5% TFA (in 1.0 L). The analysis was performed using a 
binary linear gradient, along with a flow rate gradient (Table 1). The analysis was performed 
at 40°C, with an initial mobile phase flow rate of 0.55 mL min−1.
2.8. Specificity and selectivity
Interference from endogenous compounds was investigated using six male and female blank 
plasma samples, and blank plasma samples injected during each analytical run. Interference 
from 20 antiretroviral drugs was evaluated, including the drug classes of protease inhibitors, 
nucleoside analogue reverse transcriptase inhibitors and non-nucleoside analogue reverse 
transcriptase inhibitors. Also, a set of commonly used medications with different 
physicochemical properties was investigated (such as the lipid-lowering agent atorvastatin, 
Lipitor).
2.9. Limits of quantification and limit of detection
The lower limit of quantification (LLOQ) was defined as the concentration for which both 
the relative standard deviation (CV%) and the percent deviation from the nominal 
concentration (dev%) were less than 20%. The upper limit of quantification (ULQ) was 
defined as the concentration for which both the relative standard deviation and the percent 
deviation from the nominal concentration were less than 15% [7, 8]. The detection limit was 
defined as a signal-to-nose ratio of 3:1.
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HIV-infected patient samples are routinely heated at 58 °C for 30 minutes to inactivate the 
virus prior to handling. Therefore, heat deactivation studies were performed to verify the 
stability of RAL in plasma under these conditions. An additional stability test was 
performed to verify the integrity of the drugs in the autosampler tubes while waiting for 
HPLC analysis. The stability during sample handling was also verified by subjecting 
samples to three freeze-thaw cycles. Quality controls (QC) samples at three concentrations 
(0.06 mgL−1, 0.6 mgL−1, and 6.0 mgL−1) were utilized for stability testing.
2.11. Clinical sample analysis
To assure the applicability of the method, clinical samples were studied and represented in 
this work. Every sample was analyzed in triplicate at standard and diluted (50μL sample
+50μL blank plasma) concentrations. These clinical samples were obtained from patients on 
different antiretroviral regimens (listed in Table 7).
3 Results
3.1 Linearity, limit of quantification
Peak area RAL: IS ratios for the calibration standards were proportional to the concentration 
of raltegravir in plasma over the range tested. The calibration curves were fitted by linear 
weighted least-squares regression. The linear regression data for the calibration curves of the 
method (n=6) consistently demonstrated coefficients of determination >0.998, with a slope 
CV of 1.45%. The method was linear from 0.02–10,0 mgL−1. The low limit of 
quantification of RAL was 0.02 mgL−1 with low percent deviation and high precision as 
shown in Table 2. Linearity was also tested without the internal standard to determine the 
direct proportionality of RAL peak areas with their corresponding concentrations. The 
regression coefficient (r2 ) of all calibration curves was ≥ 0.999.
3.2 Selectivity and specificity
The approximate retention times for RAL and IS were 6.71 and 9.73 min, respectively. No 
endogenous substances interfered with the analyte or internal standard in blank plasma 
extracts. Figure 2b illustrates a chromatogram of extracted blank plasma with internal 
standard demonstrating no endogenous substance interference. In order to evaluate the 
complete separation of other antiretroviral compound peaks from the RAL peak, a 
chromatogram of 20 antiretrovirals is overlaid with the method system stability in Figure 2a. 
This figure demonstrates excellent separation of the RAL and IS peaks from the other 
analytes. Six additional potentially co-administered agents also had retention times that were 
very different from the compound of interest and internal standard.
Column selection is demonstrated in Figures 2b, 2c and, 2d. These three figures represent 
the separation of RAL and IS from 20 other antiretrovirals. Table 3a describes the 
parameters compared in column selection. Table 3b lists all of the compounds injected 
individually and their respective retention times on the Symmetry column.
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Results of the method validation are shown in Table 4. All observed data (intra-day and 
inter-day precision [CV]) were at or below 15%, and in accordance with the FDA guidelines 
[13]. Accuracy and precision at the lower and upper limits of quantification are presented in 
Table 2b. Chromatograms of the three QC concentrations are illustrated in Figure 3a (0.06 
mgL−1 ), 3b (0.6 mgL−1 ) and 3c (6.0 mgL−1). The accuracy of RAL, represented as percent 
deviation from the nominal concentration, ranged from 0.6% to 4.3% for all three 
concentrations for both within-day and between-day analysis. The method’s precision for 
RAL was always within 7.9% for both within- day and between-day analysis.
3.4. Extraction efficiency (recovery %)
The extraction efficiencies of RAL and IS from plasma using the described SPE method 
were calculated using the ratio of the analyte’s concentration in blood plasma to the identical 
concentrations of the analyte prepared in mobile phase without extraction. Figure 4 
illustrates raltegravir’s extraction efficiency for 14 columns investigated during the SPE 
selection process. In this investigation, the Bond Elute C18 Varian column with 100mg of 
packing material yielded the highest extraction efficiency, at approximately 80%. Further 
optimization of the method yielded a final extraction method with consistent high recoveries 
for RAL and IS as listed in Table 5. The mean percent recovery was 90.3% for RAL and 
90.0% for the IS.
3.5. Stability
Raltegravir has previously been found to be stable at room temperature in human blood 
plasma, and under long term storage [4]. The results of RAL stability under various 
conditions tested are shown in Table 6. The drug proved to be stable under all conditions. 
Concentrations measured at the end of the test period were within 1.1%, 1.2% and 8.7% of 
the initial concentrations for three freeze-thaw cycles, heat deactivation, and a final extract 
held at room temperature for 24 hours, respectively. Table 5 demonstrates that the stability 
of RAL in plasma under heat deactivation conditions for HIV is better than RAL in a final 
extract form at room temperature for 24 hours. Because of this, it is recommended that the 
final extract be kept at 4C°, and samples fed frequently to the autosampler if a refrigerated 
autosampler is not available.
3.6. Application of the method on patient samples
The method was successfully applied to eleven plasma samples of HIV-infected individuals. 
Sample results, along with concurrent antiretroviral therapy, are listed in Table 7. Samples 
were analyzed in triplicate, with also partial volume dilution. Dilution results support 
performing the assay using one-half of the volume (50 μL). Figure 5 is a representative 
chromatogram of patient sample #10, with a calculated concentration of 0.202 mgL−1. This 
method encompasses the peak and trough concentrations expected in patients [5].
4. Discussion
Raltegravir is active against a wide range of wild-type and multidrug-resistant HIV-1 
clinical isolates and has potent activity against viruses using CCR5 and/or CXCR4 co-
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receptors for entry [9, 10]. As part of our mission to develop simple, universal methods of 
quantifying drug concentrations in biological matrices, a high-performance liquid 
chromatography method with UV detection was developed and validated. Since RAL may 
be combined with multiple antiretroviral agents, in addition to optimizing accuracy and 
precision over a wide dynamic range, we were focused on the following objectives: 
obtaining sharp RAL peaks that were well resolved from other potentially co-administered 
agents, obtaining high extraction efficiency from blood plasma, and reducing the required 
sample volume.
The resultant optimized HPLC method provided very good separation from all other 
antiretroviral drugs tested. In the analytical column selection process, the Restek column 
provided a poor peak shape and lack of resolution of RAL from other antiretrovirals. Using 
the peak height:peak area ratio as a measure of peak sharpness, the Restek column had the 
lowest ratios for both RAL and the IS. Using the Atlantis and Zorbax columns improved the 
peak shapes, but saquinavir eluted too close to the IS. Since the Symmetry C18 column 
resolved all analytes with no IS interference, it was chosen for further method development. 
This column had been previously used by Notari et al [11] for the simultaneous 
determination of 16 antiretroviral drugs. Using this Symmetry column with a smaller 
particle size ensured optimal separation and a shortened run time, as illustrated in Figure 2a.
An advantage of this method is the use of a minimum amount of ion pairing reagent: 0.5mM 
of TBAP was enough to completely resolve RAL and its IS from all potentially interfering 
drugs. Using a minimum amount of ion pairing reagent lengthens the life of the column and 
preserves the ruggedness of the method. Additionaly, this method is applicable to any simple 
binary HPLC system, as it uses a standard mobile phase and gradient elution.
Merschman et al [4] used liquid-liquid extraction for RAL using 1:1 mixture of 
hexane:methylene chloride and a plasma buffered to a pH of 4.0. This extraction method 
was also used in the publications of Long et al [5] and Poirier et al [6]. Although the 
extraction efficiency was good (~87%), we were not successful in curbing the variability of 
this technique from one run to the next (CV% of 22 to 12%). This large variation in 
recovery might have been due to the difficulty in separating the lower organic layer of 
hexane:methylene chloride from the upper aqueous layer of plasma. Therefore, a SPE 
method was pursued. This method offers both higher extraction efficiency and excellent 
reproducibility.
The extraction conditions were optimized to be selective for RAL and its internal standard 
of choice. In the washing step, 5% methanol in buffer was found to give the cleanest 
baseline. In the elution step, an acidic pH was required to elute RAL from the column. We 
tested TFA, perchloric acid and acetic acid in methanol at various methanolic 
concentrations. Acetic acid 1.5% in methanol was found to be an excellent choice for eluting 
RAL. Using a higher concentration of acid eluted un wanted endogenous components into 
the final extract. We believe this extraction method is also more suitable for developing 
multiplex methods of antiretroviral agents. Most other antiretroviral agents can be extracted 
with our SPE method [12–15], whereas very few can be extracted with the hexane-
methylene chloride method. This becomes particularly important for laboratories with 
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limited instrumentation and manpower, whereby putting up multiple methods is not practical 
or feasible. This assay was successfully used in measuring RAL concentrations in clinical 
samples. Figure 4 illustrates the chromatogram for RAL in a patient (#10 in Table 7) taking 
6 antiretroviral agents in combination.
With one exception, under all conditions tested, RAL was stable. Resultant concentrations 
were at least 90.3% or higher of the initial concentration. However, in a final extract left at 
room temperature for high QC within 24 hours, RAL did not pass our stability cut-off. 
Therefore, if a refrigerated auto sampler is not available, we recommend that the final 
extract be kept at 4C° and that samples are added to auto sampler every 12 hours.
5. Conclusion
This accurate, specific, and highly reproducible HPLC method for the quantification of 
raltegravir in blood plasma was well validated. The assay spans the concentration range of 
clinical interest and can easily be implemented in a standard bioanalytical laboratory. This 
method proved to be applicable for analyzing samples from HIV-1 infected patients treated 
with many different combinations of antiretroviral medications.
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Chemical structure of raltegravir and the internal standard diazepam
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Figure 2a. Chromatogram of the assay using a Symmetry C18 column. No interference from 
20 other antiretroviral medications is seen with the overlay of the method system suitability.
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Figure 2b. Chromatogram of the assay using an Atlantis C18 column. Interference from 
some of the 20 other antiretroviral medications is seen with the overlay of the method 
system suitability.
Figure 2c. Chromatogram of the assay using a Zorbax, SB, C18 column. Interference from 
some of the 20 other antiretroviral medications is suspected with the overlay of the method 
system suitability. Figure 2d. Chromatogram of the assay using a Restek IBD, C18 column. 
Interference from some of the 20 other antiretroviral medications is seen with the overlay of 
the method system suitability.
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Figure 3a. Chromatogram of low quality control sample (0.06 mgL−1 ).
Figure 3b Chromatogram of medium quality control sample (0.6 mgL−1 ).
Figure 3c Chromatogram of high quality control sample (6.0 mgL−1 ).
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SPE Column Comparison During Optimization of Extraction Method For Accubond C-18 
and Bond Elute C-18 columns, white bars represent 100mg of packing material, and grey 
bars represent 200mg of packing material. For Strata C-18, the white bar represents 50mg of 
packing material and grey bar represents 100mg of packing material. For Focus, the white 
bar represents 10mg of packing material and the grey bar represents 20mg of packing 
material.
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Chromatogram of patient sample containing 0.202 mgL−1 RAL.
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Table 1
Mobile phase and flow rate gradient program of the method HPLC system.
Time (min) Mobile Phase A (%) Mobile Phase B (%) Flow rate mL min−1
0 73 27 0.55
10 27 77 0.60
11 3 97 0.70
14 3 97 0.70
15 73 27 0.55













Rezk et al. Page 18
Table 2
Inter-assay reproducibility from calibration standard (n=6)
Nominal concentration (mgL−1) Back calculated (mgL−1) Deviation (%) RSD (%)
0.0200 0.0200 2.0 4.0
0.0500 0.0500 0.2 8.6
0.1000 0.0930 −6.8 5.7
0.5000 0.4798 −4.0 1.6
1.0000 0.9820 −1.8 1.9
5.0000 5.0898 1.8 2.7
10.0000 10.7697 7.7 2.2
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Table 3b
Retention times for drugs that may be used concomitantly in HIV-infected patients, to test for analytical 
method interference.
Drug name Retention time (min) Drug name Retention time (min)
Zalcitabine 1.23 Delavirdine 7.54
Lamivudine 1.24 Atazanavir 7.80
Chlorhexidine 1.33 Gemfibrozil 7.81
Acyclovir 1.39 Amprenavir 8.02
Tenofovir 1.56 Darunavir 8.08
Didanosine 1.62 Nelfinavir 8.39
Emtricitabine 1.75 Saquinavir 8.64
Abacavir 1.80 Atorvastatin 8.80
Stavudine 1.84 Ritonavir 11.41
Zidovudine 2.18 Propranolol 11.91
Acetylsalicylic acid 2.23 Efavirenz 12.22
Nevirapine 3.30 Lopinavir 12.51
Indinavir 5.93 Tipranavir 13.59
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Table 5
Stability of RAL with heat deactivation, three freeze-thaw cycles, and final extract left in the autosampler. All 
values are represented as the mean of the percent of initial concentration. All samples were performed in 
triplicate.
Concentration mgL−1 Heat deactivation Three freeze-thaw cycles 24hr Auto sampler room temperature
0.0600 103.1 98.2 90.3
0.6000 92.5 100.2 98.4
6.0000 101.0 98.0 85.1
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